Sugi Predict

Sugi Predict / Compounds / SCHEMBL1749060

SCHEMBL1749060

SCHEMBL1749060

COCCOc1cc2c(cc1OC)c(-c1cc3c(Cl)ccnc3n1S(=O)(=O)c1ccc(C)cc1)cn2C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 3/20 0.37
▸ TP53 P04637 1/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ PKM P14618 1/20 0.33
▸ KDR P35968 4/20 0.33
▸ EPHA2 P29317 1/20 0.33
▸ EPHB4 P54760 1/20 0.33
▸ FGFR1 P11362 2/20 0.33
▸ FLT1 P17948 2/20 0.33
▸ PCSK9 Q8NBP7 1/20 0.33
▸ MAPT P10636 2/20 0.32
▸ KIT P10721 1/20 0.32
▸ EED O75530 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748775 0.94 PTGDR2 (0.37) PTGDR2TP53IGF1RPKMKDR
SCHEMBL1748718 0.93 PTGDR2 (0.39) PTGDR2TP53IGF1RPKMKDR
SCHEMBL1749146 0.93 PTGDR2 (0.36) PTGDR2TP53IGF1RPKMKDR
SCHEMBL1749273 0.89 PTGDR2 (0.39) PTGDR2TP53IGF1RPCSK9ALDH3A1
SCHEMBL1749112 0.86 KIT (0.36) KDREPHA2EPHB4FLT1KIT
SCHEMBL1749119 0.86 IGF1R (0.44) PTGDR2TP53IGF1RPCSK9ALDH1A1
SCHEMBL4502452 0.86 KIT (0.38) KDREPHA2EPHB4FLT1KIT
SCHEMBL1749121 0.84 IGF1R (0.40) PTGDR2TP53IGF1RPCSK9MAPT
SCHEMBL1748733 0.84 HRH3 (0.40) KDREPHA2EPHB4KITMEN1
SCHEMBL1748509 0.84 TP53 (0.42) PTGDR2TP53PKMKDREPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 — — US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 — — US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 — — US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 PTGDR2 806/4885TP53 966/4885IGF1R 817/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 PTGDR2 806/4885TP53 966/4885IGF1R 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.